应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09969 诺诚健华
交易中 02-05 11:31:47
11.770
+0.390
+3.43%
最高
11.870
最低
11.340
成交量
386.50万
今开
11.380
昨收
11.380
日振幅
4.66%
总市值
207.39亿
流通市值
175.84亿
总股本
17.62亿
成交额
4,531万
换手率
0.26%
流通股本
14.94亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
智通财经 · 42分钟前
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
诺诚健华(688428)披露证券变动月报表,2月4日股价上涨1.8%
证券之星 · 02-04 22:26
诺诚健华(688428)披露证券变动月报表,2月4日股价上涨1.8%
诺诚健华:公司预计2025年度首次实现扭亏为盈
证券日报 · 02-04 21:38
诺诚健华:公司预计2025年度首次实现扭亏为盈
每日卖空追踪 | 诺诚健华 02月04日卖空量成交14.5万股,卖空比例为2.65%
市场透视 · 02-04 16:30
每日卖空追踪 | 诺诚健华 02月04日卖空量成交14.5万股,卖空比例为2.65%
283只医药股披露2025年业绩预告:药明康德最能赚、创新药企业走向盈利分界线,疫苗企业业绩承压
每经网 · 02-03 18:52
283只医药股披露2025年业绩预告:药明康德最能赚、创新药企业走向盈利分界线,疫苗企业业绩承压
每日卖空追踪 | 诺诚健华 02月02日卖空量成交92.3万股,卖空比例为8.61%
市场透视 · 02-02 16:30
每日卖空追踪 | 诺诚健华 02月02日卖空量成交92.3万股,卖空比例为8.61%
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每日经济新闻 · 02-02
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每周股票复盘:诺诚健华(688428)预计2025年净利6.33亿
证券之星 · 02-01
每周股票复盘:诺诚健华(688428)预计2025年净利6.33亿
诺诚健华(09969.HK)高开逾13%
每日经济新闻 · 01-30
诺诚健华(09969.HK)高开逾13%
股市必读:诺诚健华(688428)预计2025年全年扣非后净利润盈利约5.34亿元
中金财经 · 01-30
股市必读:诺诚健华(688428)预计2025年全年扣非后净利润盈利约5.34亿元
智通港股早知道 | 国办印发《加快培育服务消费新增长点工作方案》 金银深夜大跳水
智通财经 · 01-30
智通港股早知道 | 国办印发《加快培育服务消费新增长点工作方案》 金银深夜大跳水
诺诚健华医药有限公司 2025年年度业绩预告
新浪财经 · 01-30
诺诚健华医药有限公司 2025年年度业绩预告
诺诚健华(688428)披露2025年年度业绩预告,1月29日股价下跌1.18%
证券之星 · 01-29
诺诚健华(688428)披露2025年年度业绩预告,1月29日股价下跌1.18%
诺诚健华:公司未来会持续推进全球化战略
证券日报 · 01-29
诺诚健华:公司未来会持续推进全球化战略
诺诚健华:二级市场股价受多种因素影响
证券日报 · 01-29
诺诚健华:二级市场股价受多种因素影响
诺诚健华:预计2025年年度净利润6.33亿元 同比扭亏为盈
每日经济新闻 · 01-29
诺诚健华:预计2025年年度净利润6.33亿元 同比扭亏为盈
每日卖空追踪 | 诺诚健华 01月29日卖空量成交21.1万股,卖空比例为5.9%
市场透视 · 01-29
每日卖空追踪 | 诺诚健华 01月29日卖空量成交21.1万股,卖空比例为5.9%
每日卖空追踪 | 诺诚健华 01月27日卖空量成交13.1万股,卖空比例为4.04%
市场透视 · 01-27
每日卖空追踪 | 诺诚健华 01月27日卖空量成交13.1万股,卖空比例为4.04%
诺诚健华01月27日主力净流入56.1万元 散户资金抛售
市场透视 · 01-27
诺诚健华01月27日主力净流入56.1万元 散户资金抛售
每日卖空追踪 | 诺诚健华 01月26日卖空量成交7万股,卖空比例为1.22%
市场透视 · 01-26
每日卖空追踪 | 诺诚健华 01月26日卖空量成交7万股,卖空比例为1.22%
加载更多
公司概况
公司名称:
诺诚健华
所属市场:
SEHK
上市日期:
--
主营业务:
诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.77,"timestamp":1770262259161,"preClose":11.38,"halted":0,"volume":3865000,"delay":0,"changeRate":0.03427065026362028,"floatShares":1494000000,"shares":1762000000,"eps":-0.27,"marketStatus":"交易中","change":0.39,"latestTime":"02-05 11:31:47","open":11.38,"high":11.87,"low":11.34,"amount":45306333,"amplitude":0.046573,"askPrice":11.79,"askSize":20000,"bidPrice":11.77,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.143,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770264000000},"marketStatusCode":2,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":11.38,"openAndCloseTimeList":[[1770255000000,1770264000000],[1770267600000,1770278400000]],"volumeRatio":0.862892,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":21.86,"timestamp":1770262201000,"preClose":21.51,"halted":0,"volume":6660100,"delay":0,"premium":"-52.11"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2609346495","title":"港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346495","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609346495?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:50","pubTimestamp":1770259821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺诚健华早盘涨超4%,截至发稿,涨3.95%,报11.83港元,成交额3869.91万港元。消息面上,诺诚健华此前发布业绩预告,预计2025年实现收入23.7亿元,同比增长约134%;预计2025年归母净利润首次扭亏为盈,达6.3亿元左右。核心产品奥布替尼贡献显著增量,2025年5月坦昔妥单抗获批上市后进一步丰富药品收入来源。值得注意的是,诺诚健华宣布,公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组,总共入组383例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","688428","VT","BK4588","BK0239","BK1574","09969"],"gpt_icon":0},{"id":"2608398843","title":"诺诚健华(688428)披露证券变动月报表,2月4日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398843?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:26","pubTimestamp":1770215179,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,诺诚健华报收于21.51元,较前一交易日上涨1.8%,最新总市值为379.57亿元。该股当日开盘21.06元,最高21.72元,最低20.9元,成交额达1.91亿元,换手率为3.34%。近日,诺诚健华医药有限公司发布证券变动月报表。公司确认已符合香港联交所规定的公众持股量要求。此外,公告提及2023年及2024年人民币股份激励计划的相关安排,涉及部分限制性股票失效情况,但本月未因相关协议导致股份变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","688428","161027","09969"],"gpt_icon":0},{"id":"2608036200","title":"诺诚健华:公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2608036200","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608036200?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:38","pubTimestamp":1770212317,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日,诺诚健华在互动平台回答投资者提问时表示,公司在管线推进、商业化拓展等方面均按照计划及目标顺利推进,经营一切正常,不存在经营困境。根据公司业绩预告,公司预计2025年度首次实现扭亏为盈,预计2025年实现营业总收入人民币23.65亿元左右,与上年同期相比增长134%左右,归属于母公司所有者的净利润为6.33亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641731339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2609746343","title":"每日卖空追踪 | 诺诚健华 02月04日卖空量成交14.5万股,卖空比例为2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609746343","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609746343?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:30","pubTimestamp":1770193843,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月04日,涨1.07%,卖空量成交14.5万股,较上一交易日减少83.16%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163859a47b11a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163859a47b11a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2608875572","title":"283只医药股披露2025年业绩预告:药明康德最能赚、创新药企业走向盈利分界线,疫苗企业业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2608875572","media":"每经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608875572?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:52","pubTimestamp":1770115974,"startTime":"0","endTime":"0","summary":"Wind数据显示,截至1月31日,共有283只医药股披露了2025年业绩预告。赛诺医疗预计,公司2025年归母净利润为4300万元至5000万元,同比增长2767%至3233%。此外,披露2025年度业绩预告的医药股中,药明康德预计净利润为191.51亿元,创公司上市以来的归母净利润新高。多家创新药企业预计扭亏、减亏披露业绩预告的创新药企中,不少企业出现净利扭亏、减亏的情形。此外,盟科药业、君实生物等创新药企虽未实现盈利,但已大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","LU0320764599.SGD","01877","02359","LU2242644610.SGD","06978","09969","BK1515","BK1583","BK1576","BK1574","LU2125910500.SGD","LU0708995583.HKD","LU0052750758.USD","LU1046422090.SGD","09939","BK1141","BK1161","09995"],"gpt_icon":0},{"id":"2608850327","title":"每日卖空追踪 | 诺诚健华 02月02日卖空量成交92.3万股,卖空比例为8.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608850327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608850327?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021042,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月02日,跌1.79%,卖空量成交92.3万股,较上一交易日减少84.83%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163929a4729156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163929a4729156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯,2月2日,诺诚健华官微宣布,公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组,总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展,有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照,旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK1161","688428","BK4134","BK0239","III"],"gpt_icon":0},{"id":"2608072758","title":"每周股票复盘:诺诚健华(688428)预计2025年净利6.33亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072758?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:55","pubTimestamp":1769882111,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,诺诚健华报收于21.4元,较上周的20.29元上涨5.47%。本周,诺诚健华1月30日盘中最高价报22.5元。诺诚健华当前最新总市值377.63亿元,在化学制药板块市值排名12/150,在两市A股市值排名553/5184。业绩披露要点诺诚健华发布业绩预告,预计2025年全年归属净利润盈利约6.33亿元。公司公告汇总诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元,同比增长134%左右。扣除非经常性损益后的净利润为5.34亿元左右,同比增加9.74亿元左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","09969","688428"],"gpt_icon":0},{"id":"2607628066","title":"诺诚健华(09969.HK)高开逾13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607628066","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607628066?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:36","pubTimestamp":1769736987,"startTime":"0","endTime":"0","summary":"每经AI快讯,诺诚健华(09969.HK)高开逾13%,截至发稿,涨13.6%,报13.2港元,成交额1099.56万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636358961.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636358961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK1574","BK1161","09969","BK0239"],"gpt_icon":0},{"id":"2607050701","title":"股市必读:诺诚健华(688428)预计2025年全年扣非后净利润盈利约5.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050701","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050701?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:06","pubTimestamp":1769731601,"startTime":"0","endTime":"0","summary":"业绩预告诺诚健华发布业绩预告,预计2025年全年扣非后净利润盈利约5.34亿元;预计2025年全年归属净利润盈利约6.33亿元。诺诚健华医药有限公司2025年年度业绩预告诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元,同比增长134%左右;预计2025年度归属于母公司所有者的净利润为6.33亿元左右,同比增加10.74亿元左右,首次实现扭亏为盈;扣除非经常性损益后的净利润为5.34亿元左右,同比增加9.74亿元左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260130/31984716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688428","09969"],"gpt_icon":0},{"id":"2607705765","title":"智通港股早知道 | 国办印发《加快培育服务消费新增长点工作方案》 金银深夜大跳水","url":"https://stock-news.laohu8.com/highlight/detail?id=2607705765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607705765?lang=zh_cn&edition=full","pubTime":"2026-01-30 06:53","pubTimestamp":1769727237,"startTime":"0","endTime":"0","summary":"国务院办公厅印发《加快培育服务消费新增长点工作方案》国务院办公厅日前印发《加快培育服务消费新增长点工作方案》,旨在优化和扩大服务供给,促进服务消费提质惠民,为经济高质量发展提供有力支撑。《工作方案》提出3方面支持政策。三是通过健全标准体系、加强信用建设、强化财政金融支持等,加强对培育服务消费新增长点的支持保障。金银价格深夜大跳水!本次出售的累计收益占公司最近一期经审计归属于上市公司股东净利润的34.21%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4588","09969","BK1161","06979","BK1574","BK1192","BK4585"],"gpt_icon":1},{"id":"2607062467","title":"诺诚健华医药有限公司 2025年年度业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2607062467","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607062467?lang=zh_cn&edition=full","pubTime":"2026-01-30 06:05","pubTimestamp":1769724300,"startTime":"0","endTime":"0","summary":"(二)业绩预告情况经财务部门初步测算,诺诚健华医药有限公司预计2025年实现营业总收入人民币23.65亿元左右,与上年同期相比增长134%左右。公司预计2025年度首次实现扭亏为盈。综合以上影响,公司2025年药品总销售收入实现快速增长。2025年,公司持续推进全球化进程,全年达成两项BD交易。诺诚健华医药有限公司董事会2026年1月30日","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130072621a4665f84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130072621a4665f84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09939","BK1515","09969"],"gpt_icon":0},{"id":"2607361810","title":"诺诚健华(688428)披露2025年年度业绩预告,1月29日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607361810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607361810?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:57","pubTimestamp":1769698630,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘,诺诚健华报收于20.15元,较前一交易日下跌1.18%,最新总市值为355.58亿元。该股当日开盘20.35元,最高20.74元,最低19.96元,成交额达1.31亿元,换手率为2.41%。近日,诺诚健华医药有限公司发布2025年年度业绩预告。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2607384830","title":"诺诚健华:公司未来会持续推进全球化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607384830","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607384830?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694643,"startTime":"0","endTime":"0","summary":"证券日报网讯1月29日,诺诚健华在互动平台回答投资者提问时表示,公司与Zenas交易不仅为公司带来了实质性的即期财务收益,进一步增强了公司的现金储备与资产结构,里程碑付款可以为公司带来可持续的现金流与长期收益,此次合作也将有助于最大化奥布替尼在全球范围内的临床与商业价值,使产品能够更快惠及全球患者,也充分体现了公司创新资产的国际竞争力与长期商业潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428","BK1161","BK0239","BK1574"],"gpt_icon":0},{"id":"2607038418","title":"诺诚健华:二级市场股价受多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2607038418","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607038418?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694642,"startTime":"0","endTime":"0","summary":"诺诚健华:二级市场股价受多种因素影响","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","688428","BK1161","BK0239"],"gpt_icon":0},{"id":"2607704567","title":"诺诚健华:预计2025年年度净利润6.33亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704567","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704567?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:40","pubTimestamp":1769676015,"startTime":"0","endTime":"0","summary":"每经AI快讯,1月29日,诺诚健华公告,公司预计2025年度首次实现扭亏为盈,归属于母公司所有者的净利润为6.33亿元左右,上年同期为亏损4.41亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635268968.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635268968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"gpt_icon":0},{"id":"2607062440","title":"每日卖空追踪 | 诺诚健华 01月29日卖空量成交21.1万股,卖空比例为5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607062440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607062440?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:30","pubTimestamp":1769675444,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间01月29日,跌0.43%,卖空量成交21.1万股,较上一交易日减少14.23%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164319a463eee9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164319a463eee9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2606787495","title":"每日卖空追踪 | 诺诚健华 01月27日卖空量成交13.1万股,卖空比例为4.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787495","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606787495?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:30","pubTimestamp":1769502646,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间01月27日,涨0.52%,卖空量成交13.1万股,较上一交易日减少54.2%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164325a45b419d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164325a45b419d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2606787444","title":"诺诚健华01月27日主力净流入56.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787444","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606787444?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:16","pubTimestamp":1769501767,"startTime":"0","endTime":"0","summary":"01月27日, 诺诚健华股价涨0.52%,报收11.69元,成交金额3761.3万元,换手率0.22%,振幅2.58%,量比0.57。诺诚健华今日主力资金净流入56.1万元,上一交易日主力净流出118.3万元。该股近5个交易日下跌5.71%,主力资金累计净流出1551.9万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出726.6万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162652a45b2e93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162652a45b2e93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2606924880","title":"每日卖空追踪 | 诺诚健华 01月26日卖空量成交7万股,卖空比例为1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606924880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606924880?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:30","pubTimestamp":1769416243,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间01月26日,跌1.52%,卖空量成交7万股,较上一交易日减少83.57%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126164400a6ad7bcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126164400a6ad7bcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.1246},{"period":"3month","weight":-0.2081},{"period":"6month","weight":-0.3467},{"period":"1year","weight":1.0653},{"period":"ytd","weight":-0.0748}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.5,"avgChangeRate":0.118826},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}